IL321433A - 2,6,9-trisubstituted purines - Google Patents
2,6,9-trisubstituted purinesInfo
- Publication number
- IL321433A IL321433A IL321433A IL32143325A IL321433A IL 321433 A IL321433 A IL 321433A IL 321433 A IL321433 A IL 321433A IL 32143325 A IL32143325 A IL 32143325A IL 321433 A IL321433 A IL 321433A
- Authority
- IL
- Israel
- Prior art keywords
- amino
- alkyl
- purin
- group
- ethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (23)
1. A compound having the structure of Formula (I): (I), or a pharmaceutically acceptable salt thereof, wherein: R is selected from the group consisting of C1-6-alkyl, halo-C1-6-alkyl, and cyclopropyl; R is selected from the group consisting of -NHR, , and ; one of R and R is hydrogen and the other of R and R is selected from the group consisting of hydrogen, halogen, C1-3-alkyl, halo-C1-3-alkyl, and C1-3-alkoxy; R is selected from the group consisting of C1-6-alkyl, C3-6-cycloalkyl, -NRR, pyrazolyl, and imidazolyl; wherein the C1-6-alkyl and C3-6-cycloalkyl are optionally substituted with one or more substituents independently selected from halogen and C1-3-alkoxy; and the pyrazolyl and imidazolyl are optionally substituted with one or more substituents independently selected from C1-3-alkyl; R is C1-10-alkyl or , wherein the C1-10-alkyl is substituted with hydroxy or oxo, and is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C3-6-cycloalkyl, and tetrahydrofuranyl; 273 R is hydrogen or C1-3-alkyl; R is hydrogen; and R is selected from the group consisting of hydrogen, C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy-C1-6-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl; wherein the C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy-C1-6-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl are optionally substituted with one or more substituents independently selected from halogen; or R and R together with the nitrogen atom to which they are attached form a 4-, 5-, or 6-membered saturated monocyclic ring wherein the remaining ring atoms are carbon atoms, and wherein the monocyclic ring is optionally substituted with one or more substituents independently selected from halogen.
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has the structure of Formula (I-A): (I-A), and wherein R, R, R, R, and R are as defined in claim 1.
3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of C1-3-alkyl and halo-C1-3-alkyl.
4. The compound of any of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R is -NHR.
5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R is C1-10-alkyl, wherein the C1-10-alkyl is substituted with hydroxy, and is optionally substituted with 274 one or more substituents independently selected from the group consisting of halogen, C3-6-cycloalkyl, and tetrahydrofuranyl.
6. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R is C2-6-alkyl, wherein the C2-6-alkyl is substituted with hydroxy.
7. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R is .
8. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of , , , and .
9. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R is , wherein: R is selected from the group consisting of C1-3-alkyl, halo-C1-3-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-3-alkyl, and tetrahydrofuranyl; R is selected from the group consisting of hydrogen and C1-3-alkyl; and 275 R is selected from the group consisting of hydrogen, C1-3-alkyl, and halo-C1-3-alkyl.
10. The compound of any of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R and R are each hydrogen.
11. The compound of any of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R is -NRR; R is hydrogen; and R is selected from the group consisting of hydrogen, C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy-C1-6-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl; wherein the C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy-C1-6-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl are optionally substituted with one or more substituents independently selected from halogen.
12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R is C1-6-alkyl, wherein the C1-6-alkyl is optionally substituted with one or more substituents independently selected from halogen.
13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound has a structure selected from the group consisting of: N NN NRR NHNSOO R (I-1) (I-2) (I-3) N NN NRR NHNSOO R (I-4) (I-5) (I-6) 276 (I-7) (I-8) (I-9) (I-10) (I-11) (I-12) (I-13) (I-14) (I-15) (I-16) (I-17) (I-18) 277 (I-19) (I-20) (I-21) (I-22) (I-23) (I-24) (I-25) (I-26) (I-27) (I-28) (I-29) (I-30) 278 (I-31) (I-32) (I-33) (I-34) (I-35) (I-36) (I-37) (I-38) (I-39) (I-40) (I-41) (I-42) (I-43) (I-44) (I-45) 279 (I-46) (I-47) (I-48) (I-49) (I-50) (I-51) (I-52) (I-53) (I-54) (I-55) (I-56) (I-57) (I-58) (I-59) (I-60) 280 (I-61) (I-62) (I-63) (I-64) (I-65) (I-66) (I-67) (I-68) (I-69) (I-70) (I-71) (I-72) (I-73) (I-74) (I-75) 281 (I-76) (I-77) (I-78) (I-79) (I-80) (I-81) (I-82) (I-83) (I-84) (I-85) (I-86) (I-87) (I-88) (I-89) (I-90) 282 (I-91) (I-92) (I-93) (I-94) (I-95) (I-96) (I-97) (I-98) (I-99) (I-100) (I-101) (I-102) 283 (I-103) (I-104) (I-105) (I-106) (I-107) (I-108) (I-109) (I-110) (I-111) (I-112) (I-113) (I-114) 284 (I-115) (I-116) (I-117) wherein, as applicable: R is selected from the group consisting of C1-6-alkyl, halo-C1-6-alkyl, and cyclopropyl; R is selected from the group consisting of -NHR, , and ; one of R and R is hydrogen and the other of R and R is selected from the group consisting of hydrogen, halogen, C1-3-alkyl, halo-C1-3-alkyl, and C1-3-alkoxy; R is selected from the group consisting of C1-6-alkyl, C3-6-cycloalkyl, -NRR, pyrazolyl, and imidazolyl; wherein the C1-6-alkyl and C3-6-cycloalkyl are optionally substituted with one or more substituents independently selected from halogen and C1-3-alkoxy; and the pyrazolyl and imidazolyl are optionally substituted with one or more substituents independently selected from C1-3-alkyl; R is C1-10-alkyl or , wherein the C1-10-alkyl is substituted with hydroxy or oxo, and is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C3-6-cycloalkyl, and tetrahydrofuranyl; R is hydrogen or C1-3-alkyl; 285 R is hydrogen; R is selected from the group consisting of hydrogen, C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy-C1-6-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl; wherein the C1-6-alkyl, C3-6-cycloalkyl, C1-6-alkoxy-C1-6-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl are optionally substituted with one or more substituents independently selected from halogen; or R and R together with the nitrogen atom to which they are attached form a 4-, 5-, or 6-membered saturated monocyclic ring wherein the remaining ring atoms are carbon atoms, and wherein the monocyclic ring is optionally substituted with one or more substituents independently selected from halogen; R is selected from the group consisting of C1-3-alkyl, halo-C1-3-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-3-alkyl, and tetrahydrofuranyl; R is selected from the group consisting of hydrogen and C1-3-alkyl; R is selected from the group consisting of hydrogen, C1-3-alkyl, and halo-C1-3-alkyl; and R is selected from the group consisting of hydrogen and C1-3-alkyl.
14. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein, as applicable: R is selected from the group consisting of C1-3-alkyl, halo-C1-3-alkyl, and cyclopropyl; R is -NHR; R is hydrogen and R is selected from the group consisting of hydrogen and C1-3-alkyl; or R is hydrogen and R is selected from the group consisting of hydrogen, halogen, and C1-3-alkyl; R is selected from the group consisting of C1-6-alkyl, C3-6-cycloalkyl, -NRR, pyrazolyl, and imidazolyl; wherein the C1-6-alkyl and C3-6-cycloalkyl are optionally substituted with one or more substituents independently selected from halogen and C1-3-alkoxy; and the pyrazolyl and imidazolyl are optionally substituted with one or more substituents independently selected from C1-3-alkyl; 286 R is C1-10-alkyl, wherein the C1-10-alkyl is substituted with hydroxy, and is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C3-6-cycloalkyl, and tetrahydrofuranyl; R is hydrogen; R is selected from the group consisting of hydrogen, C1-3-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl; wherein the C1-3-alkyl, tetrahydrofuranyl, and 1,4-dioxanyl-C1-3-alkyl are optionally substituted with one or more substituents independently selected from halogen; or or R and R together with the nitrogen atom to which they are attached form an azetidinyl ring, and wherein the azetidinyl ring is optionally substituted with one or more substituents independently selected from halogen; R is selected from the group consisting of C1-3-alkyl, halo-C1-3-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-3-alkyl, and tetrahydrofuranyl; R is selected from the group consisting of hydrogen and C1-3-alkyl; R is selected from the group consisting of hydrogen, C1-3-alkyl, and halo-C1-3-alkyl; and R is selected from the group consisting of hydrogen and C1-3-alkyl.
15. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein, as applicable: R is selected from the group consisting of C1-3-alkyl and fluoro-C1-3-alkyl; R is -NHR; R is hydrogen and R is selected from the group consisting of hydrogen and methyl; or R is hydrogen and R is selected from the group consisting of hydrogen, fluoro, and methyl; R is selected from the group consisting of C1-3-alkyl, C3-6-cycloalkyl, -NRR, pyrazolyl, and imidazolyl; wherein the C1-6-alkyl and C3-6-cycloalkyl are optionally substituted with one or more substituents independently selected from fluoro and methoxy; and the pyrazolyl and imidazolyl are optionally substituted with one or more methyl; 287 R is C2-6-alkyl, wherein the C2-6-alkyl is substituted with hydroxy, and is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, C3-6-cycloalkyl, and tetrahydrofuranyl; R is hydrogen; R is selected from the group consisting of hydrogen, C1-3-alkyl, tetrahydrofuranyl, and 1,4-dioxanylmethyl; wherein the C1-3-alkyl, tetrahydrofuranyl, and 1,4-dioxanylmethyl are optionally substituted with one or more substituents independently selected from halogen; R is selected from the group consisting of C1-3-alkyl, fluoro-C1-3-alkyl, C3-6-cycloalkyl, C3-6-cycloalkylmethyl, and tetrahydrofuranyl; R is selected from the group consisting of hydrogen and C1-3-alkyl; R is selected from the group consisting of hydrogen, C1-3-alkyl, and halo-C1-3-alkyl; and R is selected from the group consisting of hydrogen and C1-3-alkyl.
16. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein, as applicable: R is selected from the group consisting of C1-3-alkyl and fluoro-C1-3-alkyl; R is -NHR; R is selected from the group consisting of hydrogen and fluoro; R is hydrogen; R is selected from the group consisting of C1-3-alkyl, cyclopropyl, -NRR, pyrazolyl, and imidazolyl; wherein the C1-6-alkyl and cyclopropyl are optionally substituted with one or more substituents independently selected from fluoro and methoxy; and the pyrazolyl and imidazolyl are optionally substituted with one or more methyl; R is C2-6-alkyl, wherein the C2-6-alkyl is substituted with hydroxy, and is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, C3-6-cycloalkyl, and tetrahydrofuranyl; 288 R is hydrogen; R is selected from the group consisting of hydrogen, C1-3-alkyl, tetrahydrofuranyl, and 1,4-dioxanylmethyl; wherein the C1-3-alkyl, tetrahydrofuranyl, and 1,4-dioxanylmethyl are optionally substituted with one or more fluoro; R is selected from the group consisting of methyl, ethyl, fluoroethyl, cyclopropyl, cyclopropylmethyl, cyclopentyl, and tetrahydrofuranyl; R is selected from the group consisting of hydrogen and methyl; and R is selected from the group consisting of hydrogen, methyl, and fluoromethyl.
17. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein, as applicable: R is selected from the group consisting of methyl, ethyl, isopropyl, fluoromethyl, and difluoromethyl; R is -NHR; R and R are hydrogen; R is selected from the group consisting of methyl, fluoromethyl, trifluoromethyl, methoxyethyl, cyclopropyl, -NRR, imidazolyl, pyrazolyl, methylimidazolyl, and methylpyrazolyl; R is C2-6-alkyl, wherein the C2-6-alkyl is substituted with hydroxy, and is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, C3-6-cycloalkyl, and tetrahydrofuranyl; R is hydrogen; R is selected from the group consisting of of hydrogen, methyl, ethyl, difluoroethyl, trifluoroethyl, tetrahydrofuranyl, and 1,4-dioxanylmethyl; R is selected from the group consisting of methyl, ethyl, fluoroethyl, cyclopropyl, cyclopropylmethyl, cyclopentyl, and tetrahydrofuranyl; R is selected from the group consisting of hydrogen and methyl; and 289 R is selected from the group consisting of hydrogen, methyl, and fluoromethyl.
18. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of: (S)-3-((9-ethyl-2-(1-oxoisoindolin-4-yl)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-((R)-1-hydroxy-2,3-dihydro-1H-inden-4-yl)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-((R*)-1-hydroxy-1-methyl-2,3-dihydro-1H-inden-4-yl)-9H-purin-6-yl)-amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-sulfonamide; (S)-N-(2,2-difluoroethyl)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((9-ethyl-2-(((S)-2-oxopentan-3-yl)amino)-9H-purin-6-yl)amino)-pyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((9-ethyl-2-(((2S,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)-amino)pyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((S)-2-oxopentan-3-yl)amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((9-ethyl-2-(((2S,3R)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)-amino)pyrrolidine-1-sulfonamide; 290 (S)-N-ethyl-3-((9-ethyl-2-(((R)-2-oxopentan-3-yl)amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((9-ethyl-2-(((2R,3R)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-3-((2-(((R)-1-cyclopropyl-2-hydroxyethyl)amino)-9-(difluoromethyl)-9H-purin-6-yl)-amino)-N-ethylpyrrolidine-1-sulfonamide; 2-cyclopentyl-2-((9-isopropyl-6-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)ethan-1-ol; 2-((9-isopropyl-6-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-2-(tetrahydrofuran-2-yl)ethan-1-ol; (R)-2-((6-(((3R*,4R*)-1-((1H-imidazol-2-yl)sulfonyl)-4-fluoropyrrolidin-3-yl)amino)-9-ethyl-9H-purin-2-yl)amino)-2-cyclopropylethan-1-ol; (S)-3-((2-(((2S,3R)-1,3-dihydroxybutan-2-yl)amino)-9-ethyl-9H-purin-6-yl)amino)-N-((R)-tetrahydrofuran-3-yl)pyrrolidine-1-sulfonamide; (S)-3-((2-(((R)-1-cyclopropyl-2-hydroxyethyl)amino)-9-methyl-9H-purin-6-yl)amino)-N-ethylpyrrolidine-1-sulfonamide; (R)-2-((9-isopropyl-6-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl)-amino)-9H-purin-2-yl)-amino)-3-methylbutan-1-ol; (S)-3-((9-ethyl-2-(((3S,4R)-1,1,1-trifluoro-4-hydroxypentan-3-yl-)-amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)-N-((S)-tetrahydrofuran-3-yl)pyrrolidine-1-sulfonamide; (S)-N-(((S)-1,4-dioxan-2-yl)methyl)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)-amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (2R,3S)-3-((9-ethyl-6-(((S)-1-((3-fluoroazetidin-1-yl)sulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)pentan-2-ol; 291 (S)-N-(((R)-1,4-dioxan-2-yl)methyl)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)-amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (3R*,4R*)-3-((2-(((R)-1-cyclopropyl-2-hydroxyethyl)amino)-9-methyl-9H-purin-6-yl)-amino)-N-ethyl-4-fluoropyrrolidine-1-sulfonamide; (R)-2-(6-((S)-1-(cyclopropylsulfonyl)pyrrolidin-3-yl)amino)-9-isopropyl-9H-purin-2-ylamino)-3-methylbutan-1-ol; (R)-2-(9-ethyl-6-((S)-1-(methylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-(9-cyclopropyl-6-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl-amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-cyclopropyl-2-((9-isopropyl-6-(((S)-1-(methylsulfonyl)-pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)ethanol; (2R,3S)-3-((9-isopropyl-6-(((S)-1-(1-methyl-1H-pyrazol-4-yl-sulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)pentan-2-ol; (2R,3S)-3-((9-isopropyl-6-(((S)-1-(1-methyl-1H-imidazol-4-yl-sulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)pentan-2-ol; (R)-2-((6-(((3R,4R)-4-fluoro-1-(methylsulfonyl)pyrrolidin-3-yl)amino)-9-isopropyl-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-((9-isopropyl-6-(((3S,5R)-5-methyl-1-(methylsulfonyl)-pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-((9-isopropyl-6-(((3S,5S)-5-methyl-1-(methylsulfonyl)-pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-((9-isopropyl-6-(((3S,4R)-4-methyl-1-(methylsulfonyl)-pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (2R,3S)-3-((9-isopropyl-6-(((3S,5R)-5-methyl-1-(methylsulfonyl)-pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)pentan-2-ol; 292 (R)-2-((9-ethyl-6-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)butan-1-ol; (R)-2-cyclopropyl-2-((9-ethyl-6-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)ethanol; (R)-2-((9-ethyl-6-(((S)-1-(2,2,2-trifluoroethylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-((6-(((S)-1-(cyclopropylsulfonyl)pyrrolidin-3-yl)amino)-9-ethyl-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-((9-ethyl-6-(((S)-1-((2-methoxyethyl)sulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (R)-2-((9-ethyl-6-(((S)-1-(fluoromethylsulfonyl)pyrrolidin-3-yl)amino)-9H-purin-2-yl)amino)-3-methylbutan-1-ol; (S)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((S)-2-oxopentan-3-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((S)-2-hydroxy-2-methylpentan-3-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((S)-2-hydroxy-2-methylpentan-3-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((S)-1-hydroxybutan-2-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((2R*,3S*)-4,4,4-trifluoro-3-hydroxybutan-2-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-ethyl-2-(((1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; 293 (3R*,4R*)-3-((9-ethyl-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)-4-fluoro-N-methylpyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9-methyl-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-3-((9-(fluoromethyl)-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (S)-3-((9-(difluoromethyl)-2-(((2R,3S)-2-hydroxypentan-3-yl)amino)-9H-purin-6-yl)amino)-N-methylpyrrolidine-1-sulfonamide; (2R,3S)-3-((6-(((3R*,4R*)-1-((1H-imidazol-2-yl)sulfonyl)-4-fluoropyrrolidin-3-yl)-amino)-9-methyl-9H-purin-2-yl)amino)pentan-2-ol; (2R,3S)-3-((6-(((3R*,4R*)-1-((1H-imidazol-2-yl)sulfonyl)-4-fluoropyrrolidin-3-yl)-amino)-9-(difluoromethyl)-9H-purin-2-yl)amino)-1,1,1-trifluorobutan-2-ol; (S)-3-((2-(((R*)-1-cyclopropyl-3-hydroxypropan-2-yl)amino)-9-ethyl-9H-purin-6-yl)-amino)-N-ethylpyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((9-ethyl-2-(((R*)-3-hydroxy-3-methylbutan-2-yl)-amino)-9H-purin-6-yl)amino)pyrrolidine-1-sulfonamide; (S)-N-ethyl-3-((3-ethyl-5-(((2R,3S)-2-hydroxypentan-3-yl)amino)-3H-imidazo[4,5-b]pyridin-7-yl)amino)pyrrolidine-1-sulfonamide; (R)-2-((6-(((3R*,4R*)-1-((1H-imidazol-2-yl)sulfonyl)-4-fluoro-pyrrolidin-3-yl)amino)-9-(difluoromethyl)-9H-purin-2-yl)amino)-2-cyclopropylethan-1-ol; and (2R,3S)-3-((6-(((S)-1-((1H-pyrazol-5-yl)sulfonyl)pyrrolidin-3-yl)amino)-9-ethyl-9H-purin-2-yl)amino)pentan-2-ol.
19. A pharmaceutical composition comprising a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. 294
20. A method of treating cancer in a subject suffering from or susceptible to the cancer, the method comprising administering to the subject a therapeutically effective amount of a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof.
21. The method of claim 20, wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, endometrial cancer, cervical cancer, uterine cancer, gastric cancer, prostate cancer, bladder cancer, lung cancer, esophageal cancer, head and neck cancer, kidney cancer, liver cancer, pancreatic cancer, thyroid cancer, colorectal cancer, and skin cancer.
22. The method of claim 20 or 21, wherein the method further comprises administering to the subject a therapeutically effective amount of a CDK4/6 inhibitor.
23. The use of a compound of any of claims 1 to 18, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263387734P | 2022-12-16 | 2022-12-16 | |
| PCT/IB2023/062789 WO2024127350A1 (en) | 2022-12-16 | 2023-12-15 | 2,6,9-trisubstituted purines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL321433A true IL321433A (en) | 2025-08-01 |
Family
ID=89473830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL321433A IL321433A (en) | 2022-12-16 | 2023-12-15 | 2,6,9-trisubstituted purines |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20240247001A1 (en) |
| EP (1) | EP4634186A1 (en) |
| JP (1) | JP2026500305A (en) |
| KR (1) | KR20250121114A (en) |
| CN (1) | CN120359223A (en) |
| AR (1) | AR131380A1 (en) |
| AU (1) | AU2023393410A1 (en) |
| CL (1) | CL2025001706A1 (en) |
| CO (1) | CO2025009649A2 (en) |
| CR (1) | CR20250283A (en) |
| DO (1) | DOP2025000143A (en) |
| IL (1) | IL321433A (en) |
| MX (1) | MX2025006884A (en) |
| PE (1) | PE20251925A1 (en) |
| TW (1) | TWI922868B (en) |
| UY (1) | UY40564A (en) |
| WO (1) | WO2024127350A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025202991A1 (en) * | 2024-03-29 | 2025-10-02 | Astrazeneca Ab | Crystalline form of (s)-n-ethyl-3-((9-ethyl-2-(((2r,3s)-2-hydroxypentan-3-yl)amino)-9h-purin-6-yl)amino)-pyrrolidine-1-sulfonamide |
| WO2026012471A1 (en) * | 2024-07-11 | 2026-01-15 | 上海先声再明医药生物科技有限公司 | Substituted purine compound and use thereof |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| CN119462661A (en) * | 2024-09-24 | 2025-02-18 | 烟台皓元生物医药科技有限公司 | A preparation method of AZD-8421 and its intermediates |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432164A (en) | 1991-10-24 | 1995-07-11 | Novo Nordisk A/S | C2,N6 -disubstituted adenosine derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| WO1997033591A1 (en) | 1996-03-13 | 1997-09-18 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
| AU2022497A (en) | 1996-03-13 | 1997-10-01 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
| US5866702A (en) | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
| US6790958B2 (en) * | 1996-08-02 | 2004-09-14 | Robert T. Lum | Purine inhibitors of cyclin dependent kinase 2 & IKBA |
| DE19653646A1 (en) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituted purine derivatives, processes for their preparation, agents containing them and their use |
| GB9723589D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| US6479487B1 (en) * | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
| GB9813554D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| IL144675A0 (en) | 1999-02-01 | 2002-05-23 | Cv Therapeutics Inc | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α |
| GB9903762D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| FR2793794B1 (en) | 1999-05-21 | 2001-07-27 | Hoechst Marion Roussel Inc | NOVEL PURINE DERIVATIVES, THEIR PREPARATION PROCESS, THEIR APPLICATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NEW USE |
| CZ2002961A3 (en) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamides and related compounds for factor Xa inhibition |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| EP1377579B1 (en) | 2000-10-31 | 2009-03-25 | Aventis Pharmaceuticals Inc. | Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
| US20060009642A1 (en) | 2001-10-12 | 2006-01-12 | Irm Llc, A Delaware Limited Liability Company | Methods for the synthesis of substituted purines |
| CA2463563A1 (en) | 2001-10-12 | 2003-04-17 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
| AU2002334992B2 (en) | 2001-10-12 | 2009-07-02 | Irm Llc | Methods for the synthesis of substituted purines |
| JP2005535631A (en) | 2002-06-27 | 2005-11-24 | エフ.ホフマン−ラ ロシュ アーゲー | Synthesis of purine derivatives |
| WO2004069185A2 (en) | 2003-02-03 | 2004-08-19 | Cv Therapeutics Inc. | Partial and full agonists of a1 adenosine receptors |
| WO2005020892A2 (en) | 2003-08-08 | 2005-03-10 | Mitochroma Research, Inc. | Pharmaceutical compositions and methods for metabolic modulation |
| JP2007502776A (en) | 2003-08-15 | 2007-02-15 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 6-Substituted anilinopurines as RTK inhibitors |
| MXPA06013250A (en) | 2004-05-14 | 2007-02-28 | Abbott Lab | Kinase inhibitors as therapeutic agents. |
| JP2006056879A (en) | 2004-07-21 | 2006-03-02 | Kobe Univ | Insulin resistance improving agent and screening method thereof |
| US7514417B2 (en) | 2005-05-19 | 2009-04-07 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| BRPI0614502A2 (en) | 2005-07-30 | 2011-03-29 | Astrazeneca Ab | COMPOUND, PROCESS TO PREPARE THE SAME, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND |
| WO2007028022A2 (en) | 2005-09-01 | 2007-03-08 | Renovis, Inc. | Novel compounds as p2x7 modulators and uses thereof |
| GB0606283D0 (en) | 2006-03-29 | 2006-05-10 | Cyclacel Ltd | Process |
| GB0614947D0 (en) | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
| CA2676138A1 (en) | 2007-01-26 | 2008-08-07 | Irm Llc | Compounds and compositions as kinase inhibitors |
| GB0706632D0 (en) | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | New purine derivatives |
| CA2691987C (en) | 2007-06-12 | 2016-08-16 | Achaogen, Inc. | Antibacterial agents |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| WO2009034386A1 (en) | 2007-09-13 | 2009-03-19 | Astrazeneca Ab | Derivatives of adenine and 8-aza-adenine and uses thereof-796 |
| US9089572B2 (en) | 2008-01-17 | 2015-07-28 | California Institute Of Technology | Inhibitors of p97 |
| WO2009129094A2 (en) | 2008-04-15 | 2009-10-22 | Mallinckrodt Inc. | Compositions containing antiviral compounds and methods of using the same |
| EP2303881A2 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| US8377639B2 (en) | 2009-06-26 | 2013-02-19 | University Of Massachusetts | Compounds for modulating RNA binding proteins and uses therefor |
| US20130137728A1 (en) | 2010-03-24 | 2013-05-30 | MUSC Foundation for Research and Development | Compositions and Methods for the Treatment of Degenerative Diseases |
| WO2012009649A1 (en) | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Mif inhibitors and their uses |
| WO2012019093A1 (en) | 2010-08-05 | 2012-02-09 | Human Biomolecular Research Institute | Synthetic compounds and methods to decrease nicotine self-administration |
| JP2013540145A (en) | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | Selective CYP11B1 inhibitor for the treatment of cortisol-dependent diseases |
| US9133164B2 (en) | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
| DK2753605T3 (en) | 2011-09-09 | 2019-06-17 | Lantheus Medical Imaging Inc | COMPOSITIONS, METHODS AND SYSTEMS FOR THE SYNTHESIS AND THE APPLICATION OF IMAGE CRAFTS |
| US9187480B2 (en) | 2012-02-17 | 2015-11-17 | Research Triangle Institute | Peripherally restricted diphenyl purine derivatives |
| RU2661896C2 (en) | 2012-11-16 | 2018-07-23 | Мерк Шарп И Доум Корп. | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| US20140275178A1 (en) | 2013-03-13 | 2014-09-18 | Musc Foundation For Research Development | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders |
| US20150376198A1 (en) | 2013-02-18 | 2015-12-31 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| WO2014172616A2 (en) | 2013-04-18 | 2014-10-23 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| US9796714B2 (en) | 2013-05-20 | 2017-10-24 | University of Pittsburgh—of the Commonwealth System of Higher Education | Calcium channel agonists |
| WO2016011394A1 (en) | 2014-07-18 | 2016-01-21 | The General Hospital Corporation | Imaging agents for neural flux |
| CN107427521B (en) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | Inhibitors of cyclin-dependent kinases |
| US20180000814A1 (en) | 2016-06-14 | 2018-01-04 | Joseph Hacia | Compositions and methods for the treatment of zellweger spectrum disorder |
| WO2018036414A1 (en) | 2016-08-23 | 2018-03-01 | 北京诺诚健华医药科技有限公司 | Fused heterocyclic derivative, preparation method therefor and medical use thereof |
| KR101893879B1 (en) | 2017-03-31 | 2018-09-03 | 한국화학연구원 | Novel CDK inhibitory compounds, preparation method thereof, pharmaceutical composition for use in preventing or treating CDK relating diseases containing the same as an active ingredient |
| US20190029977A1 (en) | 2017-04-24 | 2019-01-31 | Mercaptor Discoveries, Inc. | Use of Thiol Compounds to Treat Neurological Disease |
| CN110582496A (en) | 2017-05-03 | 2019-12-17 | 格勒诺布尔-阿尔卑斯大学 | Methods for the synthesis of variously substituted purines |
| WO2019195056A1 (en) | 2018-04-04 | 2019-10-10 | Sigilon Therapeutics, Inc. | Methods, compositions, and implantable elements comprising stem cells |
| JP2021536458A (en) | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | Aryl Hydrocarbon Receptor Antagonists and Usage |
| JP2022506682A (en) | 2018-11-05 | 2022-01-17 | アビスタ ファーマ ソリューションズ,インコーポレーテッド | Compound |
| JP7594787B2 (en) | 2018-12-07 | 2024-12-05 | ユニバーシティ オブ メリーランド、ボルチモア | Non-ATP/catalytic site p38 mitogen-activated protein kinase inhibitors |
| CA3128155C (en) | 2019-01-31 | 2023-09-19 | Pfizer Inc. | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 |
| CN113692276B (en) | 2019-02-19 | 2026-02-27 | 加利福尼亚大学董事会 | NURR1 receptor modulators |
| WO2020181050A1 (en) | 2019-03-05 | 2020-09-10 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| CN111825674A (en) | 2019-04-22 | 2020-10-27 | 上海仕谱生物科技有限公司 | Pyrimido five-membered heterocyclic compounds and their use as mutant IDH2 inhibitors |
| CN114025758B (en) | 2019-07-01 | 2026-05-08 | 钱立刚 | P2X7R antagonist |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| CN113024563B (en) | 2019-12-24 | 2023-01-03 | 药康众拓(江苏)医药科技有限公司 | Pyrimido five-membered heterocyclic compound or pharmaceutically acceptable salt and isomer thereof, and preparation method, pharmaceutical composition and application thereof |
| US20230140941A1 (en) | 2020-03-13 | 2023-05-11 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| JP2021167301A (en) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors |
| US12653888B2 (en) | 2020-05-04 | 2026-06-16 | Sigilon Therapeutics, Inc. | Compositions, devices and methods for inducing immune responses to infectious agents |
| JP7853532B2 (en) | 2020-05-19 | 2026-04-30 | ファーマコスモス ホールディング エー/エス | Cyclin-dependent kinase inhibitor compounds for treating medical disorders |
| US20260167619A2 (en) | 2020-09-22 | 2026-06-18 | Beone Medicines I Gmbh | Indoline compounds and derivatives as egfr inhibitors |
| CN122562781A (en) | 2020-10-07 | 2026-08-14 | 上海睿跃生物科技有限公司 | Compounds and methods for treating cancer |
| EP4284415A4 (en) | 2021-01-26 | 2024-12-11 | Sigilon Therapeutics, Inc. | BIOCOMPATIBLE DEVICES FOR CELLULAR THERAPIES AND RELATED METHODS |
| CN116981473A (en) | 2021-01-26 | 2023-10-31 | 西吉隆医疗股份有限公司 | Compositions, devices and methods for treating immune-mediated inflammatory diseases |
| US20240374507A1 (en) | 2021-01-26 | 2024-11-14 | Sigilon Therapeutics, Inc. | Compositions, devices and methods for inducing antigen-specific immune tolerance |
| WO2022266190A1 (en) | 2021-06-16 | 2022-12-22 | Blueprint Medicines Corporation | Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors |
| CN117897384A (en) | 2021-06-28 | 2024-04-16 | 缆图药品公司 | CDK2 inhibitors |
| CN116813621A (en) | 2023-06-08 | 2023-09-29 | 江南大学 | 9H purine compounds and pharmaceutical compositions and uses thereof |
-
2023
- 2023-12-15 AR ARP230103410A patent/AR131380A1/en unknown
- 2023-12-15 WO PCT/IB2023/062789 patent/WO2024127350A1/en not_active Ceased
- 2023-12-15 JP JP2025534800A patent/JP2026500305A/en active Pending
- 2023-12-15 CR CR20250283A patent/CR20250283A/en unknown
- 2023-12-15 UY UY0001040564A patent/UY40564A/en unknown
- 2023-12-15 AU AU2023393410A patent/AU2023393410A1/en active Pending
- 2023-12-15 TW TW112148944A patent/TWI922868B/en active
- 2023-12-15 IL IL321433A patent/IL321433A/en unknown
- 2023-12-15 KR KR1020257023582A patent/KR20250121114A/en active Pending
- 2023-12-15 CN CN202380085626.4A patent/CN120359223A/en active Pending
- 2023-12-15 US US18/541,006 patent/US20240247001A1/en active Pending
- 2023-12-15 EP EP23836591.0A patent/EP4634186A1/en active Pending
- 2023-12-15 PE PE2025001219A patent/PE20251925A1/en unknown
-
2025
- 2025-01-27 US US19/038,077 patent/US12441744B2/en active Active
- 2025-06-11 CL CL2025001706A patent/CL2025001706A1/en unknown
- 2025-06-12 DO DO2025000143A patent/DOP2025000143A/en unknown
- 2025-06-12 MX MX2025006884A patent/MX2025006884A/en unknown
- 2025-07-16 CO CONC2025/0009649A patent/CO2025009649A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4634186A1 (en) | 2025-10-22 |
| WO2024127350A1 (en) | 2024-06-20 |
| TWI922868B (en) | 2026-04-21 |
| KR20250121114A (en) | 2025-08-11 |
| US20240247001A1 (en) | 2024-07-25 |
| JP2026500305A (en) | 2026-01-06 |
| PE20251925A1 (en) | 2025-08-05 |
| CN120359223A (en) | 2025-07-22 |
| US12441744B2 (en) | 2025-10-14 |
| MX2025006884A (en) | 2025-07-01 |
| UY40564A (en) | 2024-06-28 |
| AR131380A1 (en) | 2025-03-12 |
| CO2025009649A2 (en) | 2025-08-08 |
| TW202440578A (en) | 2024-10-16 |
| CR20250283A (en) | 2025-08-21 |
| CL2025001706A1 (en) | 2025-08-18 |
| US20250197425A1 (en) | 2025-06-19 |
| DOP2025000143A (en) | 2025-08-15 |
| AU2023393410A1 (en) | 2025-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022545542A5 (en) | ||
| JP7713934B2 (en) | Crystalline solvated forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea | |
| TWI831803B (en) | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| JP2022533260A5 (en) | ||
| RU2010137635A (en) | HETEROCYCLIC ANTI-VIRAL COMPOUNDS | |
| JP2023531390A (en) | Phthalazinone compound, its preparation method and its medical use | |
| US12338249B2 (en) | Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea | |
| ES2953834T3 (en) | Novel phthalazinone derivatives and their manufacturing procedure | |
| IL295456A (en) | Heterocyclic compounds for nr2f6 modulation | |
| IL275649B1 (en) | Irak degraders and uses thereof | |
| KR960702838A (en) | Use of INDOLOCARBAZOLE derivatives in the treatment of the pathological condition of the prostate gland | |
| CN110291097A (en) | Steroid compounds and protein-conjugates thereof | |
| US12441744B2 (en) | 2,6,9-trisubstituted purines | |
| RU2010153578A (en) | IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION | |
| JP2023504187A5 (en) | ||
| US20240174615A1 (en) | Synthesis of rapamycin analog compounds | |
| AU2022316425A1 (en) | Drug conjugate of eribulin derivative | |
| US20230135729A1 (en) | Compound with anti-spore activity and pharmaceutical composition thereof | |
| CN114644635B (en) | Triazole tricyclic derivatives, preparation method and application thereof | |
| CN114989156B (en) | Receptor interaction protein inhibitor and preparation method and application thereof | |
| NZ728685A (en) | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors | |
| NZ728685B2 (en) | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors | |
| HK40104808A (en) | Fused ring compound as protein degradation agent as well as preparation method and use thereof | |
| WO2026041050A1 (en) | Ligand-protein degrader conjugate and pharmaceutical use thereof | |
| TW202543607A (en) | Interlukin-17a inhibitors and uses thereof |